학술논문
Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition
Document Type
article
Author
Julie A. Schmidt; Georgina K. Fensom; Sabina Rinaldi; Augustin Scalbert; Paul N. Appleby; David Achaintre; Audrey Gicquiau; Marc J. Gunter; Pietro Ferrari; Rudolf Kaaks; Tilman Kühn; Anna Floegel; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Eleutherios Anifantis; Claudia Agnoli; Domenico Palli; Morena Trevisan; Rosario Tumino; H. Bas Bueno-de-Mesquita; Antonio Agudo; Nerea Larrañaga; Daniel Redondo-Sánchez; Aurelio Barricarte; José Maria Huerta; J. Ramón Quirós; Nick Wareham; Kay-Tee Khaw; Aurora Perez-Cornago; Mattias Johansson; Amanda J. Cross; Konstantinos K. Tsilidis; Elio Riboli; Timothy J. Key; Ruth C. Travis
Source
BMC Medicine, Vol 15, Iss 1, Pp 1-14 (2017)
Subject
Language
English
ISSN
1741-7015
Abstract
Abstract Background Little is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer. Methods In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure. Results Seven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p